Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment
Conditions: Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma Interventions: Drug: Ixazomib Citrate; Drug: Pevonedistat Sponsor: National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials